On Tuesday, Novo Nordisk, the manufacturer of Ozempic, announced its decision to initiate legal proceedings against its major U.S. competitor, Eli Lilly. The Danish pharmaceutical giant alleges that Eli Lilly has engaged in the dissemination of “false and materially misleading” advertisements regarding its weight-loss and diabetes medications.
According to Novo Nordisk, Eli Lilly, which produces competing weight-loss solutions Zepbound and Mounjaro, has “deliberately chosen outdated studies” that compare the highest doses of its products against lower doses of Novo Nordisk’s offerings. The Danish firm claims that Eli Lilly’s advertisements “misleadingly presented” these findings as evidence of overall superiority while neglecting to provide essential clinical context.
While Novo Nordisk has introduced a drug known as semaglutide, Eli Lilly has developed a competing medication called tirzepatide. Both drugs represent significant revenue opportunities for the respective companies.
John F. Kuckelman, the general counsel for Novo Nordisk, emphasized the need for accurate information as new treatment options emerge. “People deserve reliable information that reflects the most recent scientific findings to assist them in making informed healthcare decisions,” he stated. He also underscored that healthcare companies bear the responsibility of ensuring that their public statements are both accurate and current, noting that inadequate disclaimers do not rectify the misleading impressions created by extensive national advertising campaigns.
The source of Novo Nordisk’s grievance is an advertising campaign that has been broadcast during prominent global sporting events and has appeared on platforms such as TikTok and Facebook, leading to significant public confusion.
In response to these allegations, Eli Lilly defended its marketing strategy, asserting that the clinical trial referenced in its advertisements, known as Surmount-5, is “the only direct, head-to-head randomized clinical trial comparing tirzepatide and semaglutide in the context of weight management.” A spokesperson for Eli Lilly further noted, “Instead of competing based on the merits of its products, Novo is seeking judicial intervention to prevent Lilly from sharing the findings of this trial. We stand firmly behind our advertising efforts.”
Both medications are classified as anti-obesity treatments that mimic the action of the intestinal hormone GLP-1, and they can be utilized for weight management and/or the treatment of type 2 diabetes, the most prevalent form of the disease.
